Physician profile
Brian J Jacobs
NPI 1730146218
$12,407.72
in general payments reported to CMS, 2019-2025
25 companies · $1,077 in 2025
The $1,077 reported for 2025 was more than what 79% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,332 · 2020: $330 · 2021: $532 · 2022: $1,369 · 2023: $788 · 2024: $981 · 2025: $1,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,844.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $7,312.29 | 2019-2022 | |
| Abbvie INC. | $1,671.63 | 2022-2025 | |
| Alcon Vision LLC | $714.66 | 2019-2025 | Rocklatan, Hydrus Microstent, Clareon |
| Oyster Point Pharma, INC. | $450.24 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Aerie Pharmaceuticals, INC. | $353.31 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $292.73 | 2019-2023 | |
| Thea Pharma INC. | $202.77 | 2022-2025 | Iyuzeh |
| Sun Pharmaceutical Industries INC. | $181.52 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $177.64 | 2022-2025 | Vyzulta, Xiidra, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $153.53 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $144.98 | 2024-2025 | Xdemvy |
| Amgen INC. | $130.27 | 2024-2025 | Tepezza |
| Harrow Eye, LLC | $123.22 | 2024-2025 | Vevye |
| Sight Sciences, INC. | $91.36 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Akorn Operating Company LLC | $82.77 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $54.94 | 2020-2025 | Dextenza |
| New World Medical,INC. | $48.91 | 2022-2024 | Clearpath, Streamline, Ahmed Glaucoma Valve |
| Topcon Healthcare, INC. | $47.52 | 2025 | |
| Shire North American Group INC | $39.00 | 2019 | |
| Horizon Therapeutics Plc | $35.44 | 2023 | Tepezza |
| Glaukos Corporation | $24.38 | 2024 | Idose |
| Biotissue Holdings INC. | $22.66 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $18.61 | 2025 | Tecnis Iol |
| Mallinckrodt Hospital Products INC. | $17.56 | 2023 | Acthar |
| Carl Zeiss Meditec, INC. | $15.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.